Medpace(US:MEDP)2026-02-10 15:02Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $708.5 million, a year-over-year increase of 32%, while full year 2025 revenue reached $2.53 billion, reflecting a 20% increase from 2024 [7][9] - EBITDA for Q4 2025 was $160.2 million, up 20% from $133.5 million in Q4 2024, with a full year EBITDA of $557.7 million, an increase of 16.1% [9][10] - Net income for Q4 2025 was $135.1 million, a 15.5% increase compared to $117 million in the prior year, with full year net income at $451.1 million, representing an 11.6% increase [10][11] - The EBITDA margin for Q4 was 22.6%, down from 24.9% in the prior year, while the full year EBITDA margin was 22%, compared to 22.8% in the previous year [9][10] Business Line Data and Key Metrics Changes - Net new business awards entering backlog in Q4 increased by 39.1% year-over-year to $736.6 million, resulting in a net book-to-bill ratio of 1.04 [7][9] - Ending backlog as of December 31, 2025, was approximately $3 billion, a 4.3% increase from the prior year [7][8] Market Data and Key Metrics Changes - The company reported a backlog conversion rate of 23.6% in Q4, with an expectation that approximately $1.9 billion of backlog will convert to revenue in the next 12 months [8][9] Company Strategy and Development Direction - The company views the overall business environment as adequate and improving, with continued opportunities for growth despite elevated cancellation rates [5][6] - The company anticipates a revenue growth range of 8.9%-12.8% for 2026, with total revenue expected between $2.755 billion and $2.855 billion [12][13] Management's Comments on Operating Environment and Future Outlook - Management noted that cancellations were elevated in Q4, the highest in over a year, but expressed optimism that this trend would not continue [5][6] - The management team highlighted that the competitive landscape remains stable, with no significant changes in dynamics despite increased aggressiveness from top competitors [62][63] Other Important Information - The company repurchased 2.96 million shares for $912.9 million in 2025, with $821.7 million remaining under the share repurchase authorization program [11][12] - The effective tax rate for 2026 is projected to be between 18.5% and 19.5%, with interest income expected to be between $24.3 million and $29.2 million [12][13] Q&A Session Summary Question: What is embedded in your guidance for revenue growth excluding pass-throughs? - Management does not provide guidance on direct service revenue but expects reimbursable costs to be around 41%-42% of revenue in 2026 [16] Question: What do you expect headcount growth to be in 2026? - The company anticipates accelerated hiring in 2026, with growth in the mid to high single-digit range [17] Question: Can you unpack the business environment and RFP activity? - Management reported that RFPs were up slightly, but cancellations impacted net bookings [21] Question: Can you provide details on the cancellations? - Cancellations were widespread and not concentrated in any single project or client [27] Question: How do you view the competitive landscape? - Management sees no significant change in the competitive dynamics despite increased aggressiveness from top CROs [62][63] Question: What are your thoughts on AI's impact on the industry? - Management believes it is too early to assess AI's impact, expecting gradual changes rather than immediate productivity advantages [55][56]